Clostridium difficile

Fidaxomicin underused for C diff infections, study finds

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US hospitals remains low.

Chris Dall

VA trial finds no reduction in C diff recurrence after fecal microbiota therapy

A placebo-controlled randomized trial found fecal microbiota transplantation was safe but failed to reduce recurrence of Clostridioides difficile infection.

Chris Dall

Narrow-spectrum drug shows promise against C diff infection in phase 2 trial

The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.

Chris Dall

C difficile vaccine candidate fails to meet primary end point in phase 3 trial

The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.

Chris Dall

Study reveals how microbiota-based treatment may help prevent recurrent C diff

The analysis suggests administration of Rebyota is associated with significant restoration of microbiota and bile acid composition.

Chris Dall

Specialist-led intervention program linked to better management of C diff patients

Researchers say the findings suggest oversight of C diff patients by infectious disease specialists may result in better outcomes and resource management.

Chris Dall

Rebyota fecal transplant offers durable protection after antibiotic exposure, study finds

The treatment remained protective against recurrent C difficile infection in 86% of patients over a span of 2 years despite antibiotic exposure.

Chris Dall

Household study suggests infants may spread C difficile

A longitudinal household study found shared C difficile strains in 17 of 28 families, with the infant detected first in most instances.

Chris Dall

Strategy to prevent hospital-onset C diff shows mixed results

The CDC-developed strategy did not reduce incidence of hospital-onset C difficile over time at participating hospitals, but implementation was affected by COVID-19.

Chris Dall

New guidelines recommend fecal microbiota transplant, related therapies for most patients with recurrent C diff

The American Gastroenterological Association says the document is the first comprehensive, evidence-based guideline on the use of FMT for recurrent C difficile.

Chris Dall